王婧毅, 李博杨, 王丹阳, 齐冬梅. 基于代谢组学探讨钩藤玄参颗粒干预正常高值血压患者的作用机制J. 药学学报, 2025, 60(9): 2827-2836. DOI: 10.16438/j.0513-4870.2025-0013
引用本文: 王婧毅, 李博杨, 王丹阳, 齐冬梅. 基于代谢组学探讨钩藤玄参颗粒干预正常高值血压患者的作用机制J. 药学学报, 2025, 60(9): 2827-2836. DOI: 10.16438/j.0513-4870.2025-0013
WANG Jing-yi, LI Bo-yang, WANG Dan-yang, QI Dong-mei. Exploring the mechanism of action of Gouteng Xuanshen Granules in patients with prehypertension based on metabolomicsJ. Acta Pharmaceutica Sinica, 2025, 60(9): 2827-2836. DOI: 10.16438/j.0513-4870.2025-0013
Citation: WANG Jing-yi, LI Bo-yang, WANG Dan-yang, QI Dong-mei. Exploring the mechanism of action of Gouteng Xuanshen Granules in patients with prehypertension based on metabolomicsJ. Acta Pharmaceutica Sinica, 2025, 60(9): 2827-2836. DOI: 10.16438/j.0513-4870.2025-0013

基于代谢组学探讨钩藤玄参颗粒干预正常高值血压患者的作用机制

Exploring the mechanism of action of Gouteng Xuanshen Granules in patients with prehypertension based on metabolomics

  • 摘要: 钩藤玄参颗粒作为山东中医药大学附属医院院内制剂在降血压方面疗效显著但作用机制尚不十分明确。研究采用高效液相色谱质谱联用(high performance liquid chromatography-mass spectrometry, HPLC-MS) 技术对受试者的血清样本进行非靶向代谢组学分析并通过中药系统药理学数据库与分析平台(TCMSP) 筛选钩藤玄参颗粒活性成分, Gene Cards、OMIM等数据库对正常高值血压相关的潜在靶点进行预测分析以探讨钩藤玄参颗粒对正常高值血压(prehypertension, PHT) 的降压作用。临床招募符合诊断标准的正常高值血压患者20例为正常高值血压组(P组), 另招募20例健康志愿者为正常组(C组)。正常高值血压组服用钩藤玄参颗粒, 为钩藤玄参颗粒给药组(GT组)。本实验获得山东中医药大学附属医院伦理委员会批准, 并得到所有参与者的知情同意。伦理审查批件号: (2022) 伦审No. (036)-KY。对所有受试者进行血脂四项检测及血压测量。正常高值血压组分别在给药钩藤玄参颗粒前后采血一次, 正常组入组时采血一次。采用HPLC/MS对所有受试者血清样本进行分析, 实验结果发现, 钩藤玄参颗粒给药后, 正常高值血压患者血压明显下降, 血脂四项发生改变; 代谢组学结果显示嘌呤代谢、精氨酸生物合成和鞘脂代谢在钩藤玄参颗粒给药后发生了显著改变; 网络药理学结果提示钩藤玄参颗粒主要通过作用于SIRT1、STAT3、AKT1等靶点发挥降压作用。研究初步分析了健康人群、正常高值血压患者与钩藤玄参颗粒治疗组人群的代谢差异, 为正常高值血压的未病防治提供了参考价值。

     

    Abstract: Gouteng Xuanshen Granules, as an institutional preparation of Shandong University of Traditional Chinese Medicine Affiliated Hospital, have shown significant efficacy in reducing blood pressure, but their mechanisms of action are not yet fully understood. This study used HPLC-MS to perform non-targeted metabolomics analysis on serum samples from subjects, including those with prehypertension (PHT) and healthy individuals. TCMSP was used to identify the active components of Gouteng Xuanshen Granules. Databases like Gene Cards and OMIM were used to predict potential targets related to normal high blood pressure and to explore the antihypertensive effects of the granules on PHT. The study recruited 20 patients with prehypertension meeting the diagnostic criteria into the PHT group (Group P) and 20 healthy volunteers into the control group (Group C). The prehypertension group was administered Gouteng Xuanshen Granules (Group GT). The study was approved by the Ethics Committee of Shandong University of Traditional Chinese Medicine Affiliated Hospital, and informed consent was obtained from all participants ethical review approval number: (2022) Lun Review No. (036)-KY. All subjects underwent four lipid tests and blood pressure measurements. Blood samples were collected once before and after administration of the granules in the prehypertension group, and once at enrollment in the control group. HPLC/MS was used to analyze serum samples from all subjects. The results showed that after administration of the granules, patients with prehypertension had a significant decrease in blood pressure and changes in the four lipid parameters. Metabolomics analysis revealed significant changes in purine metabolism, arginine biosynthesis, and sphingolipid metabolism after granule administration. Network pharmacology analysis suggested that the granules primarily exert their antihypertensive effects by acting on targets such as SIRT1, STAT3, and AKT1. This study provides preliminary insights into the metabolic differences among healthy individuals, those with prehypertension, and the treatment group, offering valuable references for the prevention and treatment of prehypertension. The study preliminarily analyzed the metabolic differences among healthy individuals, patients with elevated blood pressure within the normal range, and those treated with Gouteng Xuanshen Granules, providing valuable reference for the prevention and treatment of elevated blood pressure within the normal range.

     

/

返回文章
返回